NCT07296705 2025-12-22
HARBOR
Fujian Medical University Union Hospital
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT07233252 2025-11-18
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT04004221 2024-10-26
Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
BeiGene
Phase 2 Completed
NCT05531123 2024-07-12
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Fudan University
Phase 2 Recruiting
NCT06387056 2024-04-26
SEGNO
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
NCT05957757 2023-08-31
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital
Phase 2 Recruiting
NCT05775874 2023-03-20
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
Abbisko Therapeutics Co, Ltd
Phase 2 Unknown
NCT05445648 2022-12-28
CBPTMI
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT04730219 2022-11-30
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT05401279 2022-08-18
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
RenJi Hospital
Phase 2 Unknown